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In this thesis, we studied the tumor suppressive functions of SETD2 and PBRM1 
in ccRCC development. In chapter 2, we comprehensively reviewed the literature 
concerning SETD2, from its basic biological functions to clinic relevance, especially 
for ccRCC tumors. In chapters 3 and 4, we investigated the consequences of SETD2 
and PBRM1 loss in primary tubular epithelial cells (PTECs), the proposed normal 
counterparts of ccRCC tumor cells. In chapter 5, we broadened our study to long 
non-coding RNAs (lncRNAs) in an attempt to identify lncRNAs involved in ccRCC 
development. Here, I summarize our findings, discuss the results in a broader view, and 
propose some (near-) future perspectives.
SETD2 loss in PTECs
In mammalian cells, SETD2 is the sole protein responsible for the trimethylation of 
histone H3 at lysine 36 (H3K36me3). The H3K36me3 histone mark is linked to actively 
transcribed regions. Loss of SETD2 results in loss of H3K36me3, which prohibits 
binding of H3K36me3 reader proteins to carry out their functions. Consequently, 
SETD2 deficient cells showed defects in facilitating transcription elongation, 
preventing spurious transcription initiation, RNA processing, DNA mismatch repair 
(MMR), and homologous recombination (HR) repair. These defects increase the risk 
of transformation of SETD2 deficient cells (chapter 2). SETD2-loss may also abolish 
its direct interaction with other proteins, e.g. TP53 (Xie et al., 2008). Our current 
knowledge on the direct binding partners of SETD2 is still limited, which calls for 
further investigations.
Inactivation of SETD2 prevented PTECs from senescence-induced growth arrest 
(chapter 3), an observation that has not been described before. Interestingly, SETD2-
knockdown(KD) PTECs retained expression of G2M check-point genes and E2F 
target genes at a level similar to wild type PTECs at day 6. In contrast, day 16 WT 
PTECs showed a significant downregulation of these gene sets. Subsequent RT-qPCR 
showed that the CDKN2A-E2F axis was inhibited in SETD2-KD PTECs. In addition, 
SETD2-loss conveyed PTECs with additional oncogenic expression signatures, e.g. 
genes related to Epithelial-Mesenchymal Transition (EMT). The expression of several 
lncRNAs was downregulated upon SETD2-KD. These downregulated lncRNAs showed 
further decreased levels in ccRCC cell lines (chapter 5). Similarly we also observed 
a  further downregulation of the protein coding gene expression levels in the ccRCC 
cell lines (chapter 5).
The SETD2-KD PTECs were insensitive to the normal senescence barrier, 
a known tumor suppressive mechanism. To our knowledge, this is the first functional 
study that clarifies how SETD2-loss contributes to ccRCC initiation. The inhibition 
of the CDKN2A-E2F axis in SETD2-KD PTECs caused this senescence resistance. 
Previously, Xie et al (2008) showed that SETD2 could directly interact with TP53 
to modulate a specific set of TP53 downstream genes. Interestingly, we observed 
an increased expression of CDKN1A, the TP53 downstream gene during senescence 
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induction, in SETD2-KD PTECs. Apparently, the activated TP53-CDKN1A axis 
cannot efficiently establish senescence in SETD2-KD cells. After finishing the work 
reported in the thesis chapters, as a first step to further explore this, we carried 
out a growth competition assay using lentiviral shRNA constructs against SETD2 
and against TP53. This resulted in a mixed culture of untransduced, SETD2-KD, 
TP53-KD and double-KD PTECs. We followed the relative abundance of these cells 
over time. The TP53-KD PTECs gradually decreased in abundance much alike the 
WT-PTECs. This indicates that TP53-KD alone does not prevent PTECs from going 
into senescence. However, the double-KD PTECs showed an evident proliferative 
advantage over SETD2-KD PTECs (Figure 1). This demonstrates that although TP53-
loss alone cannot prevent PTECs from going into senescence, it does promote the 
proliferation of SETD2-deficient cells. These observations are consistent with a study 
on fibroblasts by Beauséjour et al. (2003) who showed that CDKN2A is the second 
dominant and irreversible factor to establish the senescence barrier after the TP53-
CDKN1A axis, and TP53-loss could only induce a robust proliferation in the cells 
with a low expression of CDKN2A. However, It is still not clear how SETD2 mediated 
H3K36me3 modulates the expression of CDKN2A during senescence induction. 
Several factors could contribute to the decreased expression levels of CDKN2A upon 
loss of H3K36me3, i.e. gene body methylation, which is co-localized with H3K36me3 
marked regions, and positively associates with gene expression levels (Morselli et 
Figure 1. Growth competition data of SETD2-KD (A) or TP53-KD (B) PTECs with 
SETD2&TP53-KD PTEC. PTECs at passage 2 (day 0) were transduced with GFP labeled 
shRNA against SETD2 and RFP labeled shNRA against TP53 at low MOI. The percentage of 
positive fluorescence cells was determined by FACS measurement at indicated time points 
after transduction. The bars indicate the percentage of positive cells for each cell type. In panel 
A, the total number of SETD2-KD cells is set at 100% for each measurement. In panel B, the 
total number of TP53-KD cells is set at 100% for each measurement. The red bar indicates the 
percentage of SETD2/TP53 double knock-down cells at each time point. Data are shown for 
three independent experiments using three different PTEC cultures. Panel A shows that the 
double knock-down cells proliferate faster than the SETD2 knock-down cells. Panel B shows that 
the TP53 single knock-down cells have almost disappeared after 22 days.
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al., 2015). In addition, the DNA methyltransferases DNMT3 A/B can recognize the 
H3K36me3 signal through their PWWP domain for DNA methylation (Dhayalan 
et al., 2010). Thus the absence of H3K36me3 and the subsequent loss of  gene body 
methylation loss may lead to altered chromatin structure of CDKN2A gene body, and 
its decreased expression.
Besides irreversible growth arrest, senescent cells are also characterized by the 
senescence-associated secretory phenotype (SASP), the secretion of various pro-
inflammatory cytokines, chemokines, growth factors and proteases (Campisi J., 2013). 
Some of the SASP factors are able to activate the immune system to clear senescent 
cells; while some others promote cell proliferation, angiogenesis and EMT transition. 
Depending on the context, SASP can be either beneficial or harmful for cancer cells 
(Campisi J., 2013). We noticed that some of the expression signatures that were 
enriched in senescent and SETD2-KD PTECs, i.e. TNFA_SIGNALING_VIA_NFκB, 
IL6_JAK_STAT3_SIGNALING and INFLAMMATORY_RESPONSE (chapter 3), 
might be related to SASP. The effect of SETD2-KD PTECs on SASP should be further 
validated at protein level.
H3K36me3 is also present at the body of lncRNA genes. Indeed, H3K36me3 
ChIPseq was used to find new lncRNA transcripts (Derrien et al., 2012). It is thus not 
surprising that SETD2-KD PTECs also showed significant changes in the expression 
levels of lncRNA. Importantly, the downregulated lncRNAs upon SETD2-KD were 
further decreased in ccRCC tumors (chapter 5), suggesting that SETD2-loss might 
also contribute to ccRCC development through changes in lncRNA expression. 
SETD2 inactivating mutations are detected in a wide spectrum of tumors, albeit 
with low frequency. In breast cancer, SETD2 inactivation has been suggested to be 
one of the driver mutations (Stephens et al., 2012). Our new preliminary data indicate 
that SETD2 plays a role in the senescence barrier establishment in breast epithelial 
cells (data not shown). We need to confirm this and it will be attractive to investigate 
if SETD2 loss will also influence senescence in other primary epithelial cells. To this 
end, we could perform a stable SETD2-KD in a panel of primary cells, especially 
including the ones assumed to be the normal counterparts of different types of 
tumors. Studying the growth characteristics of these cells and determine presence of 
senescence by measuring β-gal activity will indicate whether SETD2 has similar roles 
in other epithelial cell types. Expression analysis of CDKN2A in SETD2-KD cells will 
clarify if SETD2/H3K36 trimethylation is a general mechanism in controlling cellular 
senescence. It is also worth investigating  if SETD2 loss results in alterations of the 
methylation status of CDKN2A gene body. To answer this question, we could perform 
bisulfite sequencing of the gene body of CDKN2A in SETD2-KD PTECs. The non-
senescent and senescent PTECs, could be included as controls respectively.
The custom designed microarray used in our study also contains both lncRNA 
probes and protein coding gene probes. This enables us to further identify putative 
senescence-associated lncRNAs. The lncRNAs that show altered expressions in 
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senescent PTECs, but remain stable in SETD2-KD PTECs, as compared to non-
senescent PTECs, are the first candidates to functionally explore. Next, we could 
determine their abundance in the nuclear and cytoplasmic fractions of the cells 
respectively. The lncRNAs that are abundant in the nuclear fraction might be relevant 
for gene expression regulation. Potential cis-regulated target genes could be identified 
by combining the expression data of lncRNAs and protein coding genes. Through this 
step-by-step filtering, the number of candidate lncRNAs will be reduced and for this 
smaller set of candidates, knockdown or overexpression studies could be performed 
to confirm its function in senescence.
PBRM1 loss in PTECs
In PBRM1-KD PTECs we did not observe evident changes in cellular proliferation, or 
in the process of senescence (chapter 4). We did observe significant expression changes 
(>2 fold) in both protein-coding genes (130 up/155 down) and lncRNAs (9 up/25 
down)(chapters 4 and 5). For protein-coding genes, the most striking changes for both 
up and downregulated genes, were related to the IFN-α and IFN-γ responsive gene 
sets. Both protein-coding genes and lncRNAs with significantly lower expression levels 
in the PBRM1-KD PTECs showed an even lower expression levels in the ccRCC cell 
lines. These downregulated genes were enriched in gene ontology annotations related 
to cell differentiation, synapse organization and cytoskeleton organization.
Previous studies on ccRCC cell lines revealed that PBRM1-loss promoted the 
cellular proliferation, migration, and colony formation (Varela et al., 2011). These 
changes were not observed upon PBRM1-KD in PTECs, which are the presumed 
normal counterparts of ccRCC. This difference might indicate that inactivation of 
PBRM1 has different roles in ccRCC initiation and progression. Recently, Benusiglio 
et al (2015) reported an inactivating PBRM1 germ line mutation in a ccRCC family, of 
which all identified mutation carriers developed ccRCC tumors. Loss of WT PBRM1 
was observed in the tumors. This reinforces the importance of PBRM1 loss as a driver 
of ccRCC development.
PBRM1 is one of the subunits specific for the PBAF subgroup of SWI/SNF complexes. 
The bromodomains of PBRM1 read histones with H3K4 acetylation (H3K4ac), 
a histone mark enriched at the promoter regions of actively transcribed genes (Wang et 
al., 2008). In this way, PBRM1 targets the PBAF complex to specific genomic segments 
to alter the local accessibility of the chromatin. The altered chromatin accessibility 
subsequently influences expression of the downstream target gene. Thirty-one genes 
that were differentially expressed upon PBRM1-KD also showed altered expression in 
ccRCC cell lines. Twenty five out of these 31 genes are linked to known biological 
processes and molecular functions, some of these 25 to multiple processes and 
functions. Gene ontology annotation revealed presence of 10 genes related to immune 
response (hormone stimulus response), 6 genes related to chromatin organization and 
transcription; 6 to cell adhesion; 11 to cellular proliferation and apoptosis.
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Aberrant expression of immune response genes upon PBMR1-KD of PTECs could 
contribute to tumor development by facilitating escape from anti-tumor responses 
(Crusz and Balkwill 2015; Giraldo et al., 2015). Gene Set Enrichment Analysis (GSEA) 
confirmed involvement of IFN-α and IFN-γ responsive gene sets upon PBRM1-KD. 
Previous studies have already shown that the SWI/SNF complexes are responsible for 
the expression of IFN responsive genes (Lemon et al., 2001; Liu et al., 2001 and 2002; 
Huang et al.,2002; Cui et al., 2004; Wang et al., 2004). However these studies did not 
always pinpoint the precise complex responsible for their findings as they focused on 
one of the subunits present in all complexes. Our data clearly demonstrate the effect of 
loss of the PBAF complex on the basal expression of IFN-α/γ responsive genes.
The preliminary data that we collected so far do not fully explain how loss of PBRM1 
functionality can be an initiating event in the development of ccRCC. To identify the 
direct target genes of PBRM1, a chromatin immunoprecipitation (ChIP) sequencing 
experiment using an antibody against PBRM1 could be considered. Overlapping 
the ChiP-seq data with the expression data will indicate which genes are the direct 
PBRM1-KD targets. In addition, an assay for transposase-accessible chromatin with 
high throughput sequencing (ATAC-seq) can also be used to identify the accessible 
DNA regions before and after PBRM1-loss. 
Our data show that the PBAF complex regulates the basal expression of IFN-α 
and IFN-γ responsive genes. It will be interesting to investigate if PBRM1 depleted 
PTECs show different expression of those genes upon IFN-α and/or IFN-γ treatment 
as compared to their wild-type counterparts. This regulation was investigated in HELA 
cells in several studies (Lemon et al., 2001; Liu et al., 2001 and 2002; Huang et al.,2002; 
Cui et al., 2004; Wang et al., 2004). These studies showed that expression of PBRM1 was 
essential for the expression of IFN responsive genes. Specifically, we could investigate if 
PBRM1 depleted ccRCC cells show differences in expression levels upon IFN treatment. 
Subsequently, we should determine if these expression changes are associated with 
the proliferation status of ccRCC. These results will help us to understand if PBRM1 
negative ccRCC cells behave differently from PBRM1 positive ccRCC upon IFN 
treatment. In addition, these investigations  may give clues for understanding why 
only part of the ccRCC patients respond to immuno-therapeutics, such as interferons 
(Leibovich et al. 2003, McDermott et al. 2005, Motzer and Molina 2009), and many of 
these patients developed therapy-resistant tumors after treatment (Sankin et al., 2015). 
In addition, it will be interesting to investigate if the immuno-treatment resistance is 
associated with the PBRM1 mutation status. If so, this could eventually make PBRM1 
mutation status an important therapy-related biomarker.
CcRCC associated lncRNAs
We identified 89 lncRNAs that were significantly differentially (>2 fold) expressed 
in ccRCC cell lines as compared to PTECs (Chapter 5). Several of them also showed 
altered expression upon SETD2-KD and PBRM1-KD in PTECs. The downregulated 
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lncRNAs upon SETD2-KD and PBRM1-KD showed further decreased expressions in 
ccRCC derived cell lines. A total of 39 putative lncRNA-protein coding RNA pairs 
were identified in ccRCC cell lines, 7 pairs in SETD2-KD PTECs, and 3 pairs in 
PBRM1-KD PTECs. 
Several lncRNAs were reported to be dysregulated in ccRCC tumors, as compared 
to the non-tumorous tissues (reviewed by Seles et al. 2016). We could only confirm 
MEG3 significantly decreased expression in ccRCC cell lines compared to PTECs. 
Comparisons between previously published microarray data did not show a lot overlap 
either. This disconcordance is probably caused by the heterogeneous nature of the 
samples. First, tissue sections are always a mixture of cell populations, containing 
both tumor cells and other normal cell types. A second reason might be the intra-
tumor heterogeneity of the ccRCC tumor itself (Gerlinger et al., 2012). This notion is 
supported by a study of Malouf et al., who categorized ccRCC tumors into 4 different 
groups based on their distinct lncRNA expression patterns (Malouf et al., 2015). 
Probably only a small number of lncRNAs are consistently differentially expressed in 
ccRCC tumors and cell lines, compared to their normal counterparts. 
MEG3 (also known as GTL2) was first identified as an imprinted gene located at 
human 14q (Miyoshi et al., 2000). In a mouse model, MEG3 has been shown with 
a dynamic expression pattern during central neural system development (McLaughlin 
et al., 2006). Cyclic-AMP (cAMP) could facilitate the binding of CREB transcription 
factors to the promoter region of MEG3 to regulate its expression, and the methylation 
of the promoter region could abolish this binding. Decreased expression of MEG3 
was also reported for non-small cell lung cancer. In these cells MEG3 functions as an 
inhibitor of proliferation and inducer of apoptosis by upregulating the TP53 level (Lu 
et al., 2013). Wang et al. (2015) observed decreased expression of MEG3 in ccRCC 
tumors, and its overexpression significantly induced the apoptosis rate in a ccRCC 
cell line. Both our data and results from other studies indicate that MEG3 is a tumor 
suppressive lncRNA that is significantly downregulated in ccRCC tumors.
It is important to further validate the expression levels of the ccRCC-associated 
lncRNAs that we identified in these cell lines in a panel of tumor samples. To reduce 
the bias caused by the heterogeneous nature of the tumors, laser microdissection 
could be used to harvest a homogeneous tumor cell population. Alternatively, RNA 
fluorescence in situ hybridization can also be used to detect lncRNA molecules in 
complex tissue samples and identify lncRNA expression directly. To study the functions 
of selected lncRNAs we could carry out knock-down and knock-in experiments in 
ccRCC cell lines, followed by monitoring the changes in proliferation, apopotosis and 
colony formation. These results  will help us to understand how lncRNA contributes 
to ccRCC development. 
In addition, the putative cis-acting lncRNA-protein coding gene pairs identified 
in our study also need further confirmation. This can help us to understand the 
interactions between lncRNAs  and their nearby protein coding genes.




Comprehensive understanding of ccRCC initiation
In this thesis, we studied the consequences of SETD2 and PBRM1 loss in PTECs 
separately, whereas the development of ccRCC is a combination of multiple aberrations. 
For a comprehensive understanding of ccRCC initiation, we need to study different 
inactivating combinations in PTECs. The shRNA based approach is limited due to the 
availability  of a limited number of fluorescent detectors. Combination of different 
inactivating events in a single cell can be achieved by first inducing loss of SETD2, 
which will allow prolonging culture of these cells and next generate stable knock-out 
cells by using a clustered regularly interspaced short palindromic repeats (CRISPR)-
Cas9 system. The CRISPR-Cas9 has been shown capable of targeting different genomic 
loci by delivering a single Cas9 enzyme with two or more single guide RNAs (sgRNAs) 
for DNA cleavage (Kabadi et al., 2014).
CcRCC tumors are characterized by loss of the entire p-arm of chromosome 3. 
So in order to study the development of ccRCC it would be interesting to mimic this 
structural aberration in PTECs. To overcome the limited proliferative capacity of 
primary PTECs, we could first use exogenous hTERT to immortalize these cells. As an 
alternative to inducing a complete loss of 3p, it might be more feasible to specifically 
deplete the 3p21 region including the PBRM1, SETD2 and BAP1 loci within a 5MB 
region. He et al. (2015) showed the feasibility of this approach by delivering two 
sgRNAs that target different genomic sites. The resulting double strand DNA breaks 
causes a genomic deletion of the region flanked by the sgRNAs. With a hemizygous 3p 
background, introduction of point mutations to the ccRCC tumor suppressor genes can 
more closely mimic the genetic aberrations occurring in ccRCC tumors. In addition the 
CRISPR-Cas9 system-mediated genome editing is at the DNA level, which results in 
a more efficient knockdown. The CRISPR-Cas9 system can also be used for correcting 
disease-associated genetic aberrations.  A relative easy approach may be to repair the 
mutations in ccRCC cell lines using the CRISPR-Cas9 and monitor phenotypes of the 
cells. Moving from studies in cell lines to that in animals could help close the gap 
between observing changes in cell lines that are speculated to lead to cancer at the 
tissue level and actual ccRCC development. Unfortunately, previous attempts to study 
ccRCC development in SETD2 and PBRM1 knockout mice were unsuccessful (Hu et 
al., 2010; Zhang et al., 2014; Wang et al., 2004). Both knockouts lead to embryonic 
lethality, caused by angiogenesis defects (SETD2-/-) or cardiac chamber development 
defects (PBRM1-/-). Using a tissue specific promoter, in combination with the Cre/
loxP or tetracycline-inducible systems to create inducible kidney epithelial cell specific 
SETD2-KO mice, might overcome this lethal phenotype. 
SETD2/H3K36me3 deficient tumor cells might be sensitive to specific treatment 
approaches. Pfister et al (Pfister et al. 2015) demonstrated that the WEE1 tyrosine 
kinase inhibitor AZD1775 promotes degradation of ribonucleotide reductase subunit 
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RRM2 through activation of CDK. The degradation of RRM2 leads to dNTP starvation 
and subsequent cell death. H3K36me3 facilitates RRM2 transcription, which implicates 
that loss of SETD2 dependent H3K36me3 will result in decreased RRM2 transcription 
levels. AZD1775 treatment of H3K36me3-deficient tumor cells is therefore expected 
to result in extremely low levels of RRM2 and subsequently lead to dNTP starvation, 
S-phase arrest, and apoptosis. Currently, there are more than 20 clinic trials at different 
phases registered in ClinicalTrails (https://clinicaltrials.gov/) to test AZD1775 efficacy 
in various tumors.
The SWI/SNF complex is also a promising target for tumor therapy using synthetic-
lethal genetic interactions (reviewed by Kaelin (2005)). Synthetic lethality means that 
an additional loss of function mutation in a gene can specifically kill tumor cells with 
a specific mutational background. Acute leukemias show defects in transcriptional 
regulators, i.e. mutations in transcription factors, DNA methylation machinery and 
so on, but mutations in SWI/SNF subunits are rarely detected. Thus the SWI/SNF 
complex appears to be important in maintaining the transcriptional program in these 
cancer cells. It has been shown that loss of BRG1 (a core component of the SWI/SNF 
complex) could increase apoptosis of leukemia cells, and block cellular differentiation. 
Meanwhile, BRG1-loss neither influenced the proliferation, nor the viability, of 
other cancer cells and fibroblasts (Shi et al., 2013), indicating the effect is cell-type 
specific. Therefore, targeting the SWI/SNF subunits in the tumors with other genetic 
aberrations may be a possible novel strategy for targeting SWI/SNF mutated tumor 
samples therapy.
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Table 1. Gene ontology analysis.
Gene symbol GO TERM
BSPRY ion transport and binding
CCR10 cellular ion homeostasis, chemokine binding
CDA regulation of cell growth, regulation of nucleotide metabolic process
CFTR cholesterol metabolic process, response to hormone stimulus
CTSA intracellular protein transport, peptidase activity
GJB4 gap junction channel activity, channel activity
HIST1H2BD chromatin organization, DNA binding
IGFBP2 regulation of cell growth, response to hormone stimulus
IL23A immune response, cell proliferation
ITGB6 inflammatory response, cell-matrix adhesion
KRAS negative regulation of apoptosis, response to hormone stimulus, positive 
regulation of NF-kappa B transcription factor activity, positive regulation of 
MAP kinase activity, Ras protein signal transduction
LOC646626 positive regulation of NF-kappa B transcription factor activity, negative 
regulation of apoptosis
MMP7 proteolysis, regulation of cell proliferation
NNAT response to glucose stimulus, regulation of hormone secretion
NT5C3 nucleoside metabolic process
PAPSS1 nucleobase, nucleoside and nucleotide biosynthetic process
PIR Transcription
PROM1 sensory perception
PRSS8 proteolysis, response to hormone stimulus
PSMB8 mitotic cell cycle, immune response
RMI2 DNA metabolic process, DNA replication
S100A4 epithelial to mesenchymal transition, calcium-dependent protein binding
SAT1 N-acetyltransferase activity
TNC cell adhesion
TNF immune response, positive regulation of NF-kappaB transcription factor 
activity, cell adhesion, negative regulation of apoptosis
Note: 31 genes, differentially expressed in both PBRM1-KD PTECs and ccRCC cell lines as compared to WT 
PTECs, were included in the analysis. The genes annotated in the DAVID resource (see chapter 4) with the GO 
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